RNA vaccine, conceptual illustration. Close-up of human cells expressing viral proteins (red) after vaccination with an RNA (ribonucleic acid, blue helix) vaccine. The viral proteins will provoke an immune response, priming the body against infection with the actual virus. The first RNA vaccine approved for human use, developed against the SARS-CoV-2 coronavirus by Pfizer/BioNTech, was approved in the UK on 2nd December 2020.
px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TPG32175230
Source:
達志影像
Authorization Type:
RF
Release Information:
須由TPG 完整授權
Model Release:
N/A
Property Release:
N/A
Right to Privacy:
No
Same folder images:
1st2019-cov2019-ncovartworkbiologicalbiologybiontechbiotechnologicalbiotechnologybnt162b2conceptsconceptualconditioncoronaviruscovid-19diseasedisorderepidemicfirsthcovhumanbodyillustrationimmunisationimmunisingimmunityimmunizingmessengerrnamrnano-onenobodypandemicpfizerribonucleicacidrnasars-covsars-cov-2vaccinatingvaccinationvaccineviralproteinantigen
1st2019-cov2019-ncovacidantigenartworkbiologicalbiologybiontechbiotechnologicalbiotechnologybnt162b2bodyconceptsconceptualconditioncoronaviruscovid-19diseasedisorderepidemicfirsthcovhumanillustrationimmunisationimmunisingimmunityimmunizingmessengermrnano-onenobodypandemicpfizerproteinribonucleicrnarnasars-covsars-cov-2vaccinatingvaccinationvaccineviral